Nano Holdings

A pioneer in regenerative medicine who established cell-sheet engineering and led its clinical application globally. Provides scientific evaluation of portfolio technologies and supports pipeline value enhancement through international research and industry-academia networks.

After working in corporate finance in Japan and Europe at Nomura Securities, he founded With Partners and managed a fund with a world-leading performance track record in the 2000s growth sector. Known for distinctive, hands-on investment strategies and strong fund-formation capabilities.

A world authority in nanotechnology who provides scientific evaluation of portfolio technologies, supports value enhancement of acquired companies, and leverages academia-industry collaboration and global networks.

A chemist with outstanding achievements in drug discovery across peptides, proteins, siRNA, and mRNA modalities. Formerly a leader at TriLink Biotechnologies and founder and CSO of Artis Biosolutions, advancing therapeutic development and manufacturing.

A healthcare industry veteran with over 30 years leading oncology drug R&D, having contributed to four blockbusters (temozolomide, sorafenib, erlotinib, crizotinib) and held CEO/CSO roles at companies including Pfizer. Has founded four ventures and brings deep fundraising, M&A, and IPO experience.

Leads US business expansion and portfolio growth at Nano Holdings US, with over 30 years of success in healthcare, technology, and environmental fields. Drove global new-business development and venture investment at Hitachi across London, San Francisco, and Tokyo, and later led ventures to IPO and M&A. A former professional racing driver.

A pharmacokinetics and clinical pharmacology expert with about 30 years at Japanese pharma companies, with experience across small molecules, protein drugs, antibodies, and nucleic-acid/mRNA medicines. Recently established an Australian subsidiary and launched a first-in-human trial.

Spent about 30 years in drug discovery at a 240-year-old pharmaceutical company, contributing to its globalization. Skilled at identifying project value across disease areas and R&D stages and coordinating global development sites.

Began in DDS anticancer drug research before moving into IR, specializing in communicating corporate value to capital markets. Supports the IR strategy of affiliated companies, optimizing R&D and growth narratives for investors.

Former senior managing director at Nitto Denko, where he grew the display materials business from hundreds of millions to hundreds of billions of yen. Former CEO of drug discovery CRO Axcelead, with deep pharmaceutical knowledge; drives portfolio value-up and carve-out strategies.

Spent 25 years in internal control and risk management at financial institutions, audit firms, and consulting companies, then served as CFO/COO of a tech venture and internal audit head of a carve-out company. Holds CIIA, CIA, and AIP certifications.

Oversees investment transaction management with over 20 years of global experience in medical and bio fields managing M&A and carve-out processes. Drove business development at Danaher HQ and led medical device launches at Leica Microsystems in Switzerland; began his career in policy at METI.

Held research, strategy, and business development roles at Kyowa Kirin, leading international alliances in antibody and cell therapy. Served as CEO of a US subsidiary and built academic and pharma networks as representative director of IP Gaia; drives value creation through business development and alliances.

An experienced executive and investor skilled in corporate growth and turnarounds, having led Japanese and foreign companies. As an MD at the Industrial Revitalization Corporation of Japan he led major restructuring deals, serves on many boards, co-founded With Partners, and has been involved in over 100 M&A deals. Harvard MBA.

Over 20 years at domestic pharma companies spanning drug discovery research, domestic and overseas clinical development, and corporate planning/new business. Evaluates products and services from a scientific standpoint and leads research to advance mRNA drug discovery.

Former executive officer/fellow at Kyowa Hakko Kirin who moved into the biotech industry. A rare scientist-executive with a track record across three modality generations — antibody drugs (mogamulizumab), nucleic-acid drugs (siRNA/ASO), and mRNA medicines.

Spent many years in corporate finance and investment banking at Daiwa Securities, oversaw corporate and IPO divisions as managing director, and later led the asset management business as president of Daiwa Fund Consulting. Also experienced in PR, IR, and corporate functions.

A fund manager with over 25 years of VC and PE experience and many successful growth investments. Prior roles include overseas technology partnerships at Hitachi, early-stage biotech support at CSK Venture Capital, and value-up of listed companies at With Partners.